Document Detail

A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids.
MedLine Citation:
PMID:  19179885     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the effect of 2 prebiotic/probiotic products on weight gain, stool microbiota, and stool short-chain fatty acid (SCFA) content of premature infants.
PATIENTS AND METHODS: This randomized, blinded, placebo-controlled trial included 90 premature infants treated with either a dietary supplement containing 2 lactobacillus species plus fructooligosaccharides (CUL, Culturelle, ConAgra, Omaha, NE), a supplement containing several species of lactobacilli and bifidobacteria plus fructooligosaccharides (PBP, ProBioPlus DDS, UAS Laboratories, Eden Prairie, MN), or placebo (a dilute preparation of Pregestamil formula) twice daily for 28 days or until discharge if earlier. The primary outcome was weight gain. Secondary outcomes were stool bacterial analysis by culture and 16S rDNA quantitative polymerase chain reaction and stool SCFA content measured by high performance liquid chromatography.
RESULTS: Both prebiotic/probiotic combinations contained more bacterial species than noted on the label. No significant effect on infant growth of either prebiotic/probiotic supplement was observed. By cultures, 64% of infants receiving PBP became colonized with bifidobacteria, compared with 18% of infants receiving CUL and 27% of infants receiving placebo (chi-square, P = 0.064). No differences were noted between groups in colonization rates for lactobacilli, Gram-negative enteric bacteria, or staphylococci. By 16S rDNA polymerase chain reaction analysis, the bifidobacteria content in the stools of the infants receiving PBP was higher than in the infants receiving CUL or placebo (Kruskal-Wallis, P = 0.011). No significant differences in stool SCFA content were detected between groups. No adverse reactions were noted.
CONCLUSIONS: Infants receiving PBP were more likely to become colonized with bifidobacteria. No significant differences in weight gain or stool SCFA content were detected.
Mark A Underwood; Nita H Salzman; Stephen H Bennett; Melissa Barman; David A Mills; Angela Marcobal; Daniel J Tancredi; Charles L Bevins; Michael P Sherman
Related Documents :
16984935 - Differential parental weight and height contributions to offspring birthweight and weig...
17649465 - Some factors influencing the losses of pigs prior to weaning.
23678195 - Breastfeeding rates in central and western china in 2010: implications for child and po...
23113145 - Child mortality rate in ethiopia.
11556475 - Successful treatment of late onset infection due to multi-drug resistant acinetobacter ...
2809915 - Identification of intrauterine growth retardation among low birth weight preterm infants.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric gastroenterology and nutrition     Volume:  48     ISSN:  1536-4801     ISO Abbreviation:  J. Pediatr. Gastroenterol. Nutr.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-30     Completed Date:  2009-06-01     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  8211545     Medline TA:  J Pediatr Gastroenterol Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  216-25     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Bifidobacterium / growth & development*
Chromatography, High Pressure Liquid
Colony Count, Microbial
Fatty Acids, Volatile / analysis*
Feces / chemistry,  microbiology
Gastrointestinal Tract / microbiology*
Gestational Age
Infant, Newborn
Infant, Premature / growth & development*
Lactobacillus / growth & development
Oligosaccharides / administration & dosage*
Polymerase Chain Reaction
Probiotics / administration & dosage*
Time Factors
Treatment Outcome
Weight Gain*
Grant Support
Reg. No./Substance:
0/Fatty Acids, Volatile; 0/Idolax; 0/Oligosaccharides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome...
Next Document:  Secondary malnutrition and overweight in a pediatric referral hospital: associated factors.